Lactosylated low density lipoprotein: a potential carrier for the site- specific delivery of drugs to Kupffer cells

MK Bijsterbosch, GJ Ziere and TJ Van Berkel

Division of Biopharmaceutics, University of Leiden, The Netherlands.

Low density lipoprotein (LDL) is a spherical particle with a diameter of 22 nm. It consists of an apolipoprotein and a lipid moiety, in which a variety of lipophilic drugs and prodrugs can be incorporated. In the present study, lactose was coupled to the apolipoprotein of LDL by reductive amination (398 +/- 40 residues/LDL particle). After injection into rats, radioactively labeled lactosylated LDL was cleared rapidly from the plasma (half-life, less than 2 min). Ten minutes after injection, the liver contained about 90% of the dose, whereas only small amounts of radioactivity were found in other tissues. Preinjection of N-acetylgalactosamine completely blocked liver uptake, whereas N-acetylglucosamine was ineffective. This indicates that the hepatic recognition site is galactose specific. Subcellular fractionation of liver indicated that the recognition of lactosylated LDL is followed by internalization and degradation of the apolipoprotein in the lysosomes. In the liver, Kupffer cells are mainly responsible for uptake. At 10 min after injection, these cells contained a 70 and 7 times higher amount of lactosylated LDL per mg of cell protein than parenchymal and endothelial cells, respectively. After galactose-specific uptake in parenchymal cells was blocked with asialofetuin, the relative concentration in Kupffer cells was even higher. The hepatic uptake of the lipid moiety of lactosylated LDL, labeled with [3H]cholesteryl oleoyl ether, was identical to that of the 125I-labeled apolipoporotein, which indicates that the particle is taken up as a unit. Thus, lactosylated LDL is taken up rapidly and selectively by Kupffer cells, and it appears that it might be a very effective vehicle for the specific delivery of lipophilic drugs, e.g., immunomodulators, to these cells.

Volume 36, Issue 3, pp. 484-489, 09/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Bartsch, A. H. Weeke-Klimp, H. W. M. Morselt, A. Kimpfler, S. A. Asgeirsdottir, R. Schubert, D. K. F. Meijer, G. L. Scherphof, and J. A. A. M. Kamps Optimized Targeting of Polyethylene Glycol-Stabilized Anti-Intercellular Adhesion Molecule 1 Oligonucleotide/Lipid Particles to Liver Sinusoidal Endothelial Cells Mol. Pharmacol., March 1, 2005; 67(3): 883 - 890. [Abstract] [Full Text] [PDF]

				R. Out, M. Hoekstra, J. A. A. Spijkers, J. K. Kruijt, M. van Eck, I. S. T. Bos, J. Twisk, and T. J. C. Van Berkel Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice J. Lipid Res., November 1, 2004; 45(11): 2088 - 2095. [Abstract] [Full Text] [PDF]

				M. K. Bijsterbosch, M. Manoharan, R. Dorland, R. van Veghel, E. A. L. Biessen, and T. J. C. van Berkel bis-Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Are Highly Selectively Taken Up by the Liver J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 619 - 626. [Abstract] [Full Text] [PDF]

				M. K. Bijsterbosch, E. T. Rump, R. L. A. D. Vrueh, R. Dorland, R. van Veghel, K. L. Tivel, E. A. L. Biessen, T. J. C. van Berkel, and M. Manoharan Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation Nucleic Acids Res., July 15, 2000; 28(14): 2717 - 2725. [Abstract] [Full Text] [PDF]

				A. J. Versluis, E. T. Rump, P. C. N. Rensen, T. J. C. van Berkel, and M. K. Bijsterbosch Stable Incorporation of a Lipophilic Daunorubicin Prodrug into Apolipoprotein E-Exposing Liposomes Induces Uptake of Prodrug via Low-Density Lipoprotein Receptor in Vivo J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 1 - 7. [Abstract] [Full Text]

				M. K. Bijsterbosch, L. J. J. W. Smeijsters, and T. J. C. van Berkel Disposition of the Acyclic Nucleoside Phosphonate (S)-9(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1146 - 1150. [Abstract] [Full Text]

				E. A. L. Biessen, H. Vietsch, J. Kuiper, M. K. Bijsterbosch, and T. J. C. v. Berkel Liver Uptake of Phosphodiester Oligodeoxynucleotides Is Mediated by Scavenger Receptors Mol. Pharmacol., February 1, 1998; 53(2): 262 - 269. [Abstract] [Full Text]

				T. Hara, Y. Tan, and L. Huang In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector PNAS, December 23, 1997; 94(26): 14547 - 14552. [Abstract] [Full Text] [PDF]

				J. A. A. M. Kamps, H. W. M. Morselt, P. J. Swart, D. K. F. Meijer, and G. L. Scherphof Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells PNAS, October 14, 1997; 94(21): 11681 - 11685. [Abstract] [Full Text] [PDF]

				J. C. Perales, G. A. Grossmann, M. Molas, G. Liu, T. Ferkol, J. Harpst, H. Oda, and R. W. Hanson Biochemical and Functional Characterization of DNA Complexes Capable of Targeting Genes to Hepatocytes via the Asialoglycoprotein Receptor J. Biol. Chem., March 14, 1997; 272(11): 7398 - 7407. [Abstract] [Full Text] [PDF]

				P. C.N. Rensen and T. J.C. van Berkel Apolipoprotein E Effectively Inhibits Lipoprotein Lipase-mediated Lipolysis of Chylomicron-like Triglyceride-rich Lipid Emulsions in Vitro and in Vivo J. Biol. Chem., June 21, 1996; 271(25): 14791 - 14799. [Abstract] [Full Text] [PDF]